Form 8-K - Current report:
SEC Accession No. 0001213900-21-065465
Filing Date
2021-12-15
Accepted
2021-12-15 16:30:40
Documents
15
Period of Report
2021-12-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea152153-8k_citiuspharm.htm   iXBRL 8-K 27839
2 PRESS RELEASE, DATED DECEMBER 15, 2021 ea152153ex99-1_citiuspharm.htm EX-99.1 91023
3 GRAPHIC ex99-1_001.jpg GRAPHIC 13982
  Complete submission text file 0001213900-21-065465.txt   366296

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20211215.xsd EX-101.SCH 3729
5 XBRL DEFINITION FILE ctxr-20211215_def.xml EX-101.DEF 26590
6 XBRL LABEL FILE ctxr-20211215_lab.xml EX-101.LAB 36592
7 XBRL PRESENTATION FILE ctxr-20211215_pre.xml EX-101.PRE 25208
8 EXTRACTED XBRL INSTANCE DOCUMENT ea152153-8k_citiuspharm_htm.xml XML 5270
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 211494533
SIC: 2834 Pharmaceutical Preparations